Sensitivity regulatory mechanism of ziprasidone capsules on PRL and FINS in male adolescents with episode schizophrenia
10.3969/j.issn.1005-1678.2016.09.009
- VernacularTitle:齐拉西酮胶囊对男性青少年首发精神分裂症患者PRL及FINS的敏感性调控机制
- Author:
Ying CHEN
;
Liang CAI
;
Jiongjiong XU
;
Chenhong XIE
- Publication Type:Journal Article
- Keywords:
ziprasidone capsules;
schizophrenia;
insulin resistance
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(9):39-41
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the sensitivity regulatory mechanism of ziprasidone capsules on prolactin( PRL) and fast insulin( FINS) in male adolescents with episode schizophrenia.Methods According to inclusion and exclusion criteria, 52 adolescent males selected from January 2015 to March 2016 were confirmed the psychiatric treatment of schizophrenia in our hospital, their ages, ziprasidone capsule usage and suffering schizophrenia stage of disease, height, waist circumference, body weight, hip circumference, and in the morning fasting blood glucose, FINS and PRL content were recorded.Mathematical model were used to calculate QUICKIFINS sensitivity index, and in accordance with the classification criteria BMI, 52 male adolescents with schizophrenia were divided into normal group and overweight group.The correlation detection, and anthropometric parameters, PRL and FINS sensitivity parameters were analysed.Results PRL and FINS, QUICKI indicators were not correlated(r=0.153, P >0.05; r=-0.101, P >0.05) statistically significant; ziprasidone capsule dose has a positive correlation with FINS(r =0.376,P <0.05), and QUICKI negative indicators (r=-0.362,P<0.05); waist-hip ratio or fat content ratio has no correlation with FINS, QUICKI indicators, but BMI and FINS has a positive correlation (r=0.389,P<0.05) and QUICKI indicators with negative correlation(r=-0.413,P<0.05);PRL level between normal group and overweight group was not statistically significant, and levels of FINS in overweight group(10.89 ±8.23) mU/L was higher than the normal group(5.79 ±3.18) mU/L, the difference was statistically significant(P <0.05).QUICKI index between the two groups was statistically significant, and the overweight of FINS was sensitivity less than the normal group.Conclusion Ziprasidone capsule has no relationship with PRL and FINS resistance in the treatment of adolescent patients with schizophrenia, while body mass index correlated with FINS resistance, and ziprasidone capsule dose correlated with FINS resistance.
